NEW YORK, Sept. 23, 2018 /PRNewswire/ -- Bernstein
Liebhard LLP, a nationally acclaimed investor rights law firm,
announces that a securities class action lawsuit has been filed on
behalf of those who purchased or acquired the securities of AbbVie
Inc. ("AbbVie" or the "Company") (NYSE:
ABBV) between October 25, 2013
and September 18, 2018, both dates
inclusive (the "Class Period"). The lawsuit seeks to recover AbbVie
shareholders' investment losses.
If you purchased AbbVie securities, and/or would like to discuss
your legal rights and options, please visit AbbVie Shareholder
Class Action Lawsuit or contact Daniel
Sadeh toll free at (877) 779-1414
or dsadeh@bernlieb.com.
According to the lawsuit, throughout the Class Period Defendants
made false and/or misleading statements and/or failed to disclose
that: (1) AbbVie's strategy to increase the sales growth of its
blockbuster drug, HUMIRA, was through illegal kickbacks and
unlawful sales and marketing tactics; (2) such practices would lead
to heightened scrutiny by State governments and agencies; and (3)
as a result, Defendants' public statements were materially false
and misleading at all relevant times. When the true details entered
the market, the lawsuit claims that investors suffered damages.
On September 18,
2018, Bloomberg reported that "California's insurance regulator is
suing AbbVie Inc., alleging that the pharmaceutical giant gave
illegal kickbacks to health-care providers in order to keep
patients on its blockbuster rheumatoid arthritis drug Humira." The
report further stated that, according to the California Department
of Insurance, "[t]he company 'engaged in a far-reaching scheme
including both classic kickbacks — cash, meals, drinks, gifts,
trips, and patient referrals — and more sophisticated ones — free
and valuable professional goods and services to physicians to
induce and reward Humira prescriptions.'"
On this news, AbbVie stock fell $4.35 per share, or over 4.5%, over two
consecutive trading days to close at $91.02 per share on September 19, 2018, damaging investors.
If you wish to serve as lead plaintiff, you must move the Court
no later than November 20, 2018. A
lead plaintiff is a representative party acting on behalf of other
class members in directing the litigation. Your ability to share in
any recovery doesn't require that you serve as lead plaintiff. If
you choose to take no action, you may remain an absent class
member.
If you purchased AbbVie securities, and/or would like to discuss
your legal rights and options, please visit
https://www.bernlieb.com/cases/abbvie-inc-abbv-lawsuit-class-action-fraud-stock-84/
https://www.bernlieb.com/cases/gds-holdings-limited-gds-class-action-lawsuit-74/or
contact Daniel Sadeh toll free at
(877) 779-1414 or dsadeh@bernlieb.com.
Since 1993, Bernstein Liebhard LLP has recovered over
$3.5 billion for its clients. In
addition to representing individual investors, the Firm has been
retained by some of the largest public and private pension funds in
the country to monitor their assets and pursue litigation on their
behalf. As a result of its success litigating hundreds of lawsuits
and class actions, the Firm has been named to The National Law
Journal's "Plaintiffs' Hot List" thirteen times and listed in
The Legal 500 for ten consecutive years.
ATTORNEY ADVERTISING. © 2018 Bernstein Liebhard LLP. The law
firm responsible for this advertisement is Bernstein Liebhard LLP,
10 East 40th Street, New York, New
York 10016, (212) 779-1414. The lawyer responsible for this
advertisement in the State of
Connecticut is Michael S. Bigin. Prior results do not
guarantee or predict a similar outcome with respect to any future
matter.
Contact Information
Daniel Sadeh
Bernstein Liebhard LLP
http://www.bernlieb.com
(877) 779-1414
dsadeh@bernlieb.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/abbvie-class-action-bernstein-liebhard-llp-announces-that-a-securities-class-action-lawsuit-has-been-filed-against-abbvie-inc---abbv-300717277.html
SOURCE Bernstein Liebhard LLP